action of glp 1 agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment type 2 diabetes | Acta Diabetologica Glucagon-Like Peptide-1 Receptor Agonists–Health Professional

This is the second head-to-head study after Eli Lilly registered its intent to carry out a Phase 3b clinical trial in April 2023 that will see the companys tirzepatide (Mounjaro) compared with Novo Nordisks semaglutide (Wegovy) 2.4mg in 700 adult participants who have obesity or overweight with weight related comorbidities without Type 2 diabetes

However, further large-scale, well-designed clinical trials are needed to determine the appropriate dosages, treatment duration, and patient selection criteria

Related Products Peptides are research compounds and are not approved for human use unless prescribed by a licensed medical practitioner.

Someone carrying extra weight who still runs half marathons, with normal blood sugar, normal labs, and good energy, has what the commission calls preclinical obesity: a state worth watching, with elevated future risk, but not necessarily one that demands aggressive treatment today